The study will evaluate the safety and immunogenicity of ONT-10 in patients with cancers which commonly express MUC1, such as breast, non-small cell lung, ovarian, colorectal, prostate, pancreatic, gastric and other cancers.
The trial consists of two parts and the ability of ONT-10 to induce both a humoral and a cellular immune response will be investigated in both parts of the study.
Oncothyreon president and chief executive officer Robert Kirkman said the trial will demonstrate in cancer patients that ONT-10 can stimulate both antibodies and immune cells directed at MUC1, as it has in animal models.
"We are also looking forward to obtaining the first human data with the adjuvant component of ONT-10, a fully synthetic lipid A analog called PET-Lipid A, which was developed at Oncothyreon," Kirkman added.